Press Releases April 15, 2026 08:00 PM

Inseego Corp. to Report First Quarter 2026 Financial Results on May 7, 2026

Inseego Corp. announces Q1 2026 financial results release date set for May 7, 2026, followed by a conference call.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
INSG

Inseego Corp., a US-based leader in 5G wireless solutions, scheduled to release its Q1 2026 financial results after market close on May 7, 2026. The company will hold an earnings call to discuss business outlook. Inseego specializes in cloud-first wireless edge technology, including 5G routers, IoT solutions, and related cloud platforms.

Inseego Corp. to Report First Quarter 2026 Financial Results on May 7, 2026
INSG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Inseego to report Q1 2026 financial results on May 7, 2026, with a conference call to follow.
  • Company focuses on 5G mobile broadband, fixed wireless access, and IoT wireless solutions with a cloud-centric platform.
  • Inseego's products include 5G routers, MiFi hotspots, and comprehensive cloud management platforms, all designed in the U.S.

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Inseego Corp. (Nasdaq: INSG) (the “Company”), a global leader in 5G mobile broadband and 5G fixed wireless access (FWA) solutions, today announced that the Company will release its financial results for the first quarter of 2026, ended March 31, 2026, after the financial markets close on May 7, 2026.

The financial statements and earnings press release will be made available at investor.inseego.com and will be filed under Inseego’s profile on EDGAR at www.sec.gov.

The Company will host a conference call that same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its results and business outlook. A live audio webcast of the conference call will be accessible from the "Investor relations" section of the Company's website at investor.inseego.com. To access the conference call, dial 1-844-282-4463 (in the U.S.) or 1-412-317-5613.

The webcast will be archived for a period of two weeks and an audio replay of the conference call will be available beginning one hour after the call and go through May 21, 2026. To hear a replay of the call, parties in the United States may call 1-855-669-9658 and enter access code 2654418 followed by the # key. International parties may call 1-412-317-0088.

About Inseego Corp.

Inseego is a leader in cloud-first wireless edge solutions, delivering secure, resilient connectivity across people, places, and machines. As wireless becomes foundational infrastructure, Inseego unifies connectivity, management, security, and subscriber lifecycle management into a platform that orchestrates cellular, satellite, Wi-Fi, and emerging wireless technologies at the edge.

Its portfolio includes 5G fixed wireless access routers, MiFi mobile hotspots IoT solutions under the Skyus brand, and cloud platforms including Inseego Connect and Inseego Subscribe, all designed in the U.S. Built on its core strength and long-term leadership in cellular technology, Inseego solutions enable service providers and channel partners to deploy and manage enterprise-grade wireless solutions at scale. Learn more at www.inseego.com.

©2026. Inseego Corp. All rights reserved. The Inseego name and logo are trademarks of Inseego Corp.

Investor Relations Contact:
Matt Glover, Gateway Group: (949) 574-3860
[email protected]


Risks

  • Uncertainty regarding the forthcoming financial results could impact investor sentiment.
  • Market competition in 5G and wireless edge technology sectors may affect growth prospects.
  • Broader economic or industry-specific factors impacting demand for 5G and IoT solutions may introduce volatility.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026